A Randomized, Double-blind, Active-controlled, Multicenter Phase III Trial to Evaluate the Efficacy and Safety of Co-administrated AD-2071 and AD-2073 in Patients With Primary Hypercholesterolemia and Essential Hypertension
Latest Information Update: 13 May 2021
At a glance
Most Recent Events
- 10 May 2021 Status changed from active, no longer recruiting to completed.
- 01 Dec 2020 Planned End Date changed from 30 May 2020 to 18 Jan 2021.
- 01 Dec 2020 Planned primary completion date changed from 30 May 2020 to 18 Jan 2021.